Radiolabelling and preclinical characterization of 89Zr-Df-radiolabelled bispecific anti-PD-L1/TGF-βRII fusion protein bintrafusp alfa.
Ingrid Julienne Georgette BurvenichYit Wooi GohNancy GuoHui Kong GanAngela RigopoulosDiana CaoZhanqi LiuUwe AckermannChristian Werner WichmannAlexander Franklin McDonaldNhi HuynhGraeme Joseph O'KeefeSylvia Jie GongFiona Elizabeth ScottLinghui LiWanping GengAnup ZutshiYan LanAndrew Mark ScottPublished in: European journal of nuclear medicine and molecular imaging (2021)
Molecular imaging of 89Zr-Df-bintrafusp alfa biodistribution was achievable and allows non-invasive quantitation of tumour uptake of 89Zr-Df-bintrafusp alfa, suitable for use in bioimaging clinical trials in cancer patients.
Keyphrases
- pet imaging
- replacement therapy
- clinical trial
- ms ms
- mass spectrometry
- positron emission tomography
- transforming growth factor
- quantum dots
- liquid chromatography tandem mass spectrometry
- smoking cessation
- stem cells
- high performance liquid chromatography
- liquid chromatography
- randomized controlled trial
- living cells
- tandem mass spectrometry
- phase ii
- signaling pathway
- bone marrow
- mesenchymal stem cells
- epithelial mesenchymal transition
- double blind